Luo Meng, Han Xue, Li Huan, Zhou Guangyue, Chen Haoxuan, Gao Fang
Department of Anesthesiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China.
Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China.
Drug Des Devel Ther. 2024 Feb 27;18:583-595. doi: 10.2147/DDDT.S451913. eCollection 2024.
Remifentanil-induced hyperalgesia (RIH) increases the risk of persistent postoperative pain, making early postoperative analgesic therapy ineffective and affecting postoperative patient satisfaction. This study aimed to verify the effects of gradual withdrawal of remifentanil combined with postoperative pump infusion of remifentanil on postoperative hyperalgesia and pain in patients undergoing laparoscopic hysterectomy.
This trial was a factorial design, double-blind, randomized controlled trial. Patients undergoing laparoscopic hysterectomy were randomly allocated to the control group, postoperative pump infusion of remifentanil group, gradual withdrawal of remifentanil group, or gradual withdrawal plus postoperative pump infusion of remifentanil group (n = 35 each). The primary outcome was postoperative mechanical pain thresholds in the medial forearm. The secondary outcomes included postoperative mechanical pain thresholds around the incision, pain numeric rating scale scores, analgesic utilization, awakening agitation or sedation scores, a 15-item quality of recovery survey, and postoperative complications.
Gradual withdrawal of remifentanil significantly increased postoperative pain thresholds versus abrupt discontinuation ( < 0.05), whereas postoperative infusion did not show significant differences compared to the absence of infusion ( > 0.05). The combined gradual withdrawal and postoperative infusion group exhibited the highest thresholds and had the lowest postoperative pain scores and analgesic requirements as well as the highest quality of recovery scores ( < 0.05). No significant differences were observed for agitation scores, sedation scores, or complication rates ( > 0.05).
The novel combined gradual withdrawal and postoperative infusion of remifentanil uniquely attenuates postoperative hyperalgesia, pain severity, analgesic necessity, and improves recovery quality after laparoscopic hysterectomy.
瑞芬太尼诱发的痛觉过敏(RIH)增加了术后持续性疼痛的风险,导致术后早期镇痛治疗无效,并影响患者术后满意度。本研究旨在验证瑞芬太尼逐渐减量联合术后泵注瑞芬太尼对腹腔镜子宫切除术患者术后痛觉过敏和疼痛的影响。
本试验为析因设计、双盲、随机对照试验。接受腹腔镜子宫切除术的患者被随机分配至对照组、术后泵注瑞芬太尼组、瑞芬太尼逐渐减量组或瑞芬太尼逐渐减量联合术后泵注组(每组n = 35)。主要结局指标为前臂内侧术后机械性疼痛阈值。次要结局指标包括切口周围术后机械性疼痛阈值、疼痛数字评分量表得分、镇痛药物使用情况、苏醒期躁动或镇静评分、15项恢复质量调查问卷以及术后并发症。
与突然停药相比,瑞芬太尼逐渐减量显著提高了术后疼痛阈值(P < 0.05),而术后泵注与未泵注相比无显著差异(P > 0.05)。逐渐减量联合术后泵注组的疼痛阈值最高,术后疼痛评分和镇痛需求最低,恢复质量评分最高(P < 0.05)。躁动评分、镇静评分或并发症发生率无显著差异(P > 0.05)。
新型的瑞芬太尼逐渐减量联合术后泵注方案能独特地减轻腹腔镜子宫切除术后的痛觉过敏、疼痛严重程度和镇痛必要性,并提高恢复质量。